Browse

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.

Ambiguous loss is at the heart of the dementia illness experience.

“They don’t want this kind of scrutiny”: Why Dr. Glaucomflecken is getting involved in protests over an Oregon hospital system’s emergency department.